Adlai Nortye (NASDAQ:ANL – Get Free Report) announced its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07, FiscalAI reports. The business had revenue of $6.53 million for the quarter, compared to analysts’ expectations of $4.72 million.
Adlai Nortye Price Performance
Shares of Adlai Nortye stock traded up $0.39 on Friday, hitting $13.25. The company’s stock had a trading volume of 56,281 shares, compared to its average volume of 409,984. Adlai Nortye has a 52-week low of $0.88 and a 52-week high of $17.25. The firm has a fifty day moving average price of $11.37 and a 200-day moving average price of $10.75.
Analyst Upgrades and Downgrades
ANL has been the subject of several analyst reports. JonesTrading started coverage on shares of Adlai Nortye in a research note on Thursday, May 14th. They issued a “buy” rating and a $22.00 price target for the company. Cantor Fitzgerald started coverage on Adlai Nortye in a research note on Monday, June 22nd. They issued an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a report on Tuesday, July 14th. Oppenheimer began coverage on shares of Adlai Nortye in a research report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 target price on the stock. Finally, HC Wainwright upped their price objective on shares of Adlai Nortye from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $24.25.
About Adlai Nortye
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Recommended Stories
- Five stocks we like better than Adlai Nortye
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
